List view / Grid view
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
29 June 2016 | By Victoria White, Digital Content Producer
Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination...
28 June 2016 | By Victoria White, Digital Content Producer
The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
15 June 2016 | By Victoria White, Digital Content Producer
Novartis' KAF156 is one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years...
10 June 2016 | By Victoria White, Digital Content Producer
Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade in adults with chronic immune thrombocytopenia...
9 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
2 June 2016 | By Victoria White, Digital Content Producer
The EC has approved Afinitor (everolimus) for the treatment of neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease...
3 May 2016 | By Victoria White, Digital Content Producer
NICE has published final draft guidance recommending trametinib in combination with dabrafenib to treat some patients with melanoma...
27 April 2016 | By Mandy Parrett, Editorial Assistant
Novartis announced today that the FDA has granted three breakthrough therapy designations for Ilaris® (canakinumab) to treat rare types of Periodic Fever Syndromes, also known as Hereditary Periodic Fevers.
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
21 April 2016 | By Victoria White, Digital Content Producer
Results from a Phase III study show Novartis’ Afinitor (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures...
